When Desmond Pedro discovered a strange hardness under his ribcage, he was just 30 and preparing for a fresh start on a government skills course. Little did he know that he would soon die of liver cancer caused by undetected hepatitis B. Sue Segar spent time with his family and spoke to experts to uncover how this overlooked virus continues to claim lives — and what can be done to stop it.
US funding for clinical research in South Africa is incrementally being cancelled. This is happening through at least two processes – the first is by banning certain kinds of foreign grants called sub-awards (which is affecting everyone globally). The second is by failing to issue routine renewals of grants for clinical studies in South Africa. Spotlight and GroundUp break down the current situation.
In late-January, the US suspended billions of dollars worth of international aid, including for HIV-related programmes in South Africa. The South African government could have responded by triggering an emergency funding mechanism but has failed to do so yet. In the meantime, activists, health researchers and even technical advisors to government are growing increasingly frustrated with the government’s lack of transparency on this issue.
Top local researchers estimate that the cancellation of funding from the US President’s Emergency Plan for AIDS Relief could lead to a significant increase in HIV infections and deaths in South Africa. Jesse Copelyn reports.
There is no shortage of myths about the cancellation of US foreign assistance. This includes the widely held misconception that PEPFAR is exempt from US aid cuts and the belief that grant terminations are just taking place in South Africa. Many of these falsehoods have been reinforced by US and South African officials. Spotlight and GroundUp dissect some of the most popular misconceptions.
After the US slashed global aid, the South African government stated that only 17% of its HIV spending relied on US funding. But some experts argue that US health initiatives had more bang for buck than the government’s programmes. Jesse Copelyn looks past the 17% figure, and considers how the health system is being affected by the loss of US money.
Amid major disruptions caused by aid cuts from the United States government, the health department aims to enrol a record number – an additional 1.1 million – of people living with HIV on life-saving antiretroviral medicine this year. Experts tell Spotlight it can’t be business as usual if this ambitious programme is to have a chance of succeeding. Ufrieda Ho reports.
Medical aid schemes will be given collective power to negotiate prices, according to draft regulations published last week. While some see the move as an important step toward reining in private healthcare prices, others argue that they do not go far enough and are legally unsound. Chris Bateman spoke to several leading experts about the proposed reforms.
It’s acknowledged in key policy documents, well known at the coalface and much ventilated in the media: South Africa’s public healthcare system has too few healthcare workers, especially medical doctors, certain specialists, and theatre nurses. Less recognised however is the shortage of public sector pharmacists. Chris Bateman lifts the lid on this until now largely hidden problem – and its impact.
The African Centre for Disease Control and World Health Organization have raised the alarm following a drastic uptick in mpox cases. This surge is being driven by a new strain of the virus. Elri Voigt reports about what we know so far and potential implications for South Africa.
With varying degrees of success, artificial intelligence has begun to play the role of research assistant, radiologist, health educator, and even therapist. In this Spotlight special briefing, Jesse Copelyn tries to see past the hype and pin-points the most immediate implications of these new technologies for healthcare in South Africa.
A Competition Commission probe recently resulted in a patent on an important tuberculosis medicine being dropped in South Africa. Twenty years ago, a similar Competition Commission case resulted in a settlement that helped drive down the prices of several antiretrovirals, thereby helping to set the stage for the country’s HIV treatment programme. Fatima Hassan and Leena Menghaney connect the dots between the two landmark cases and map out what has and has not changed over the last two decades.
